Christian Hartinger

Christian G. Hartinger (born 1974) is an Austrian-born New Zealand bioinorganic chemist known for his work in metal-based anticancer drugs.

Hartinger studied chemistry at the University of Vienna, earning his MSc in 1999 and his PhD in 2001 under Bernhard Keppler. He was an Erwin Schrödinger Fellow with Paul Dyson at the École Polytechnique Fédérale de Lausanne from 2006 to 2008 and obtained his habilitation at the University of Vienna in 2009. In 2011, Hartinger was appointed the position of Associate Professor at The University of Auckland, where he currently serves and in 2015 was promoted to Professor. He was also made deputy Head of School of Chemical Sciences in 2013.

Hartinger's research interests are in bioinorganic chemistry, medicinal chemistry, and bioanalytical chemistry, where he utilises an interdisciplinary approach in drug discovery. He is specially interested in the development of metal-centred anticancer agents, particularly ruthenium anticancer drugs, and using analytical methods to characterise their behaviour in the presence of biomolecules.

Hartinger has now published over 168 publications and has an h-index of 50.

• Meier, S. M.; Novak, M. S.; Kandioller, W.; Jakupec, M. A.; Roller, A.; Keppler, B. K.; Hartinger, C. G., Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. Dalton Trans, 2014, 43 (26), 9851-9855
• Meier, S. M.; Babak, M. V.; Keppler, B. K.; Hartinger, C. G., Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers. ChemMedChem, 2014, 9 (7), 1351-1355
• Hartinger, C. G.; Groessl, M.; Meier, S. M.; Casini, A.; Dyson, P. J., Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. Chem Soc Rev, 2013, 42 (14), 6186-6199
• Meier, S. M.; Novak, M.; Kandioller, W.; Jakupec, M. A.; Arion, V. B.; Metzler-Nolte, N.; Keppler, B. K.; Hartinger, C. G., Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. Chem Eur J, 2013, 19 (28), 9297-9307
• Kandioller, W.; Balsano, E.; Meier, S. M.; Jungwirth, U.; Göschl S.; Roller, A.; Jakupec, M. A.; Berger, W.; Keppler, B. K.; Hartinger, C. G., Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. Chem Commun, 2013, 49 (32), 3348-3350
• Meier, S. M.; Hanif, M.; Pichler, V.; Novak, M.; Jirkovsky, E.; Jakupec, M. A.; Davey, C. A.; Keppler, B. K.; Hartinger, C. G., Novel metal(II) arene 2-pyridinecarbothioamides: A rationale to orally active organometallic anticancer agents. Chem Sci, 2013, 4 (4), 1837-1846
• Babak, M. V.; Meier, S. M.; Legin, A. A.; Adib Razavi, M. S.; Roller, A.; Jakupec, M. A.; Keppler, B. K.; Hartinger, C. G., Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. Chemistry, 2013, 19 (13), 4308-4318
• Kurzwernhart, A.; Kandioller, W.; Bächler S.; Bartel, C.; Martic, S.; Buczkowska, M.; Mühlgassner, G.; Jakupec, M. A.; Kraatz, H.; Berdnarski, P. J.; Arion, V .B.; Markos, D.; Keppler, B. K.; Hartinger, C. G., Structure-activity relationships of targeted Ru^II(η⁶-p-cymene) anticancer complexes with flavonol-derived ligands. J Med Chem, 2012, 55 (23), 10512-10522